Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03335592
Other study ID # 17-203
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date January 1, 2017
Est. completion date April 1, 2022

Study information

Verified date February 2024
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Due to the emergence of multidrug-resistant micro-organisms in patients with bone and joint infection (BJI), the prescription of off-labeled antibiotics seem to be more and more common as part of routine care. These new antibiotics are, however, more expensive, and there are no precise data in France regarding the volume and cost of such off-label prescriptions in hospital, in the post-acute care structures, and in the outpatient setting. The objective of this study is to estimate the cost of using these antibiotics over 2 years for patients in a reference center for the management of complex bone and joint infection (CRIOAc)


Recruitment information / eligibility

Status Terminated
Enrollment 1000
Est. completion date April 1, 2022
Est. primary completion date April 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients having had off-label antibiotics between 2014 and 2015 to treat bone and/or joint infection, with or without implant and managed at the CRIOAc Lyon Exclusion Criteria: None

Study Design


Locations

Country Name City State
France Centre de Référence des Infections Ostéo-Articulaires complexes (CRIOAc Lyon) Lyon

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Estimation of the cost of the off-label antibiotics The molecule concerned are: daptomycin, ertapenem, linezolid, ceftaroline, tigecycline and / or colimycin.
The characteristics of the patients, the type of bone and joint infection and the prescribing methods (dosage, duration) were collected throughout the care path (hospitalization in surgery and / or medicine at CRIOAc or in peripheral hospitals, in post-acute care structure and in the home).
The duration of dispensation is about 50 days.
Overall costs for off-label prescriptions were estimated taking account of variations in purchase price invoiced to the reference center.
50 days
See also
  Status Clinical Trial Phase
Recruiting NCT05519007 - Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone N/A
Active, not recruiting NCT04563325 - Oral-only Antibiotics for Bone and Joint Infections in Children Phase 4
Recruiting NCT05341908 - Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
Recruiting NCT03550911 - Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)
Completed NCT04440631 - Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
Recruiting NCT05753215 - Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection Phase 2
Recruiting NCT05137314 - Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA) Phase 1
Not yet recruiting NCT06293352 - Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection N/A
Recruiting NCT04304885 - Effect of Sonication on Periprosthetic Joint Infection Treatment Strategy.
Completed NCT03403608 - Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections N/A
Recruiting NCT03704766 - Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis N/A
Completed NCT00974493 - Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J) Phase 4
Completed NCT03191292 - Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection N/A
Recruiting NCT06191601 - Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic Surgery
Completed NCT05804058 - Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection
Enrolling by invitation NCT04723940 - Or v IV Antibiotics for Infection Phase 3
Completed NCT03426761 - Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections Phase 4
Enrolling by invitation NCT03713528 - Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI? Phase 4
Active, not recruiting NCT06402591 - Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen. Phase 3
Completed NCT04948281 - Joint Infection Following ACL Reconstruction